









Markets
/
Stocks
/
nasdaq-fbrx
/

Forte Biosciences Inc

FBRX

27.590USD

-1.220-4.23%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

345.53MMarket Cap

LossP/E TTM



Forte Biosciences Inc

27.590

-1.220-4.23%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Forte Biosciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Forte Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 113 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 54.80.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Forte Biosciences Inc's Score

Industry at a Glance

Industry Ranking

113 / 392

Overall Ranking

246 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Forte Biosciences Inc Highlights

StrengthsRisks

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -340.16, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 582.26K shares of this stock.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

54.800

Target Price

+71.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Forte Biosciences Inc is 6.67, ranking 230 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.67

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.97

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.62

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Forte Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Forte Biosciences Inc is 6.36, ranking 289 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -340.16, which is -99.92% below the recent high of -0.26 and -28.78% above the recent low of -438.05.

Score

Industry at a Glance

Previous score

6.36

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 113/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Forte Biosciences Inc is 8.33, ranking 132 out of 392 in the Biotechnology & Medical Research industry. The average price target is 61.00, with a high of 75.00 and a low of 19.00.

Score

Industry at a Glance

Previous score

8.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

54.800

Target Price

+71.04%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Forte Biosciences Inc

FBRX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Forte Biosciences Inc is 7.30, ranking 81 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 34.44 and the support level at 21.93, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.49

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.379

Neutral

RSI(14)

46.077

Neutral

STOCH(KDJ)(9,3,3)

27.820

Sell

ATR(14)

3.752

Low Volatility

CCI(14)

-116.583

Sell

Williams %R

89.621

Oversold

TRIX(12,20)

0.806

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

31.462

Sell

MA10

31.372

Sell

MA20

31.186

Sell

MA50

26.419

Buy

MA100

20.202

Buy

MA200

15.209

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fred Alger Management, LLC

1.64M

+1.07%

Federated Hermes Global Investment Management Corp.

1.64M

+10.60%

Janus Henderson Investors

1.40M

+0.64%

OrbiMed Advisors, LLC

1.20M

Affinity Asset Advisors LLC

840.00K

Tybourne Capital Management (HK) Limited

786.65K

The Vanguard Group, Inc.

Star Investors

566.74K

+16.39%

Cable Car Capital LLC

500.00K

Sphera Funds Management Ltd.

474.31K

-4.20%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Forte Biosciences Inc is 2.12, ranking 252 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 3.24. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.